Advertisement
Advertisement

BCRX

BCRX logo

BioCryst Pharmaceuticals Inc

9.06
USD
Sponsored
-0.90
-8.99%
Sep 08, 15:56 UTC -4
Closed
exchange

After-Market

9.14

+0.08
+0.83%

BCRX Earnings Reports

Positive Surprise Ratio

BCRX beat 23 of 43 last estimates.

53%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$168.84M
/
$0.08
Implied change from Q2 26 (Revenue/ EPS)
-22.64%
/
-73.33%
Implied change from Q3 25 (Revenue/ EPS)
+5.92%
/
+33.33%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On Aug 05, 2026, BCRX reported earnings of 0.30 USD per share (EPS) for Q2 26, beating the estimate of 0.12 USD, resulting in a 148.14% surprise. Revenue reached 218.25 million, compared to an expected 186.16 million, with a 17.24% difference. The market reacted with a +0.55% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.08 USD, with revenue projected to reach 168.84 million USD, implying an decrease of -73.33% EPS, and decrease of -22.64% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
BioLineRX Ltd
Report Date
Aug 31, 2026 For Q2 26
Estimate
-
Actual
-$0.77
Surprise
-
logo
Galmed Pharmaceuticals Ltd.
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.18
Actual
$2.86
Surprise
+189.87%
FAQ
For Q2 2026, BioCryst Pharmaceuticals Inc reported EPS of $0.30, beating estimates by 148.14%, and revenue of $218.25M, 17.24% above expectations.
The stock price moved up 0.55%, changed from $9.02 before the earnings release to $9.07 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 6 analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.08 and revenue of $168.84M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement